These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 950543)

  • 1. Proceedings: Prolactin in benign and malignant breast disease.
    Cole EN; England PC; Sellwood RA; Griffiths K
    J Endocrinol; 1976 Jun; 69(3):49P-50P. PubMed ID: 950543
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum androgen levels and the menstrual cycle in women with benign or malignant breast disease.
    England PC; Sellwood RA; Knyba RE; Irvine JD
    Clin Oncol; 1981 Sep; 7(3):213-9. PubMed ID: 6211319
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prolactin. Radioimmunoassay in female breast cancers and benign mastopathies].
    Gorins A; Netter A
    Nouv Presse Med; 1974 Jan; 3(2):73-5. PubMed ID: 4815434
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum prolactin concentrations in benign breast disease throughout the menstrual cycle.
    Cole EN; Sellwood RA; England PC; Griffiths K
    Eur J Cancer (1965); 1977 Jun; 13(6):597-603. PubMed ID: 880967
    [No Abstract]   [Full Text] [Related]  

  • 5. [Determination of blood prolactin levels in breast diseases using prolactin radioimmunoassay kits (CIS-Prolak Kit)].
    Nakajima K; Saito K; Tobioka M; Ishihara K; Kobayashi T
    Horumon To Rinsho; 1976 Dec; 24(12):1303-10. PubMed ID: 1035518
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pituitary hormone level in breast cancer patients].
    Agranat VZ; Valiura AV; Nikogosian GA
    Med Radiol (Mosk); 1981 Mar; 26(3):3-8. PubMed ID: 6783807
    [No Abstract]   [Full Text] [Related]  

  • 7. Mammary cancer risk: circulating TSH and prolactin, fibrocystic breast disease in chronoepidemiologic perspective.
    Tarquini B; Benvenuti M; Legnaioli M; Bazzani M; Cagnoni M; Halberg F
    Cancer Detect Prev; 1981; 4(1-4):525-34. PubMed ID: 7349819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian variation of serum prolactin and TSH of women in health or with mammary carcinoma, fibroadenoma or fibrocystic mastopathy.
    Tarquini B; Gheri R; Romano S; Costa A; Cagnoni M; Lee JK; Halberg F
    Int J Chronobiol; 1980; 7(2):101-15. PubMed ID: 7450919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [L-dopa and prolactin in breast neoplasms and dysplasia].
    Moguilevsky L; Scacchi P; Szwarcfarb B; Barbarelli J; Moguilevsky JA
    Medicina (B Aires); 1978; 38(1):27-30. PubMed ID: 713825
    [No Abstract]   [Full Text] [Related]  

  • 10. [Study of blood copper and iron in women with benign or malignant breast diseases].
    Le Borgne de Kaouel C; Aubert C; Juret P
    Pathol Biol; 1968 Jan; 16(1):85-6. PubMed ID: 4869424
    [No Abstract]   [Full Text] [Related]  

  • 11. Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease.
    Zanetti-Dällenbach R; Wight E; Fan AX; Lapaire O; Hahn S; Holzgreve W; Zhong XY
    Anticancer Res; 2008; 28(2A):921-5. PubMed ID: 18507037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum prolactin level in healthy women and patients with functional disorders of the breast].
    Ozieblo L
    Endokrynol Pol; 1977; 28(4):323-30. PubMed ID: 891477
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma prolactin in breast cancer.
    Boyns AR; Cole EN; Griffiths K; Roberts MM; Buchan R; Wilson RG; Forrest AP
    Eur J Cancer (1965); 1973 Feb; 9(2):99-102. PubMed ID: 4717492
    [No Abstract]   [Full Text] [Related]  

  • 14. Oxidant/antioxidant status in blood of patients with malignant breast tumour and benign breast disease.
    Polat MF; Taysi S; Gul M; Cikman O; Yilmaz I; Bakan E; Erdogan F
    Cell Biochem Funct; 2002 Dec; 20(4):327-31. PubMed ID: 12415567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determining binding proteins of progesterones in patients with breast diseases].
    Kunze M; Voss P; Büttner HH; Strache RR; Röpcke G
    Zentralbl Gynakol; 1989; 111(16):1113-20. PubMed ID: 2816154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prolactin--significance in benign and malignant breast diseases].
    Pavić Z; Pavić S
    Z Lymphol; 1988 Jul; 12(1):30-5. PubMed ID: 3051756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of placental protein five (PP5) and pregnancy-specific glycoprotein (SP1) in benign and malignant breast disease.
    Bremner RD; Nisbet AD; Herriot R; Horne CH; McArdle C; Crawford D; Bohn H
    Oncodev Biol Med; 1981; 2(1-2):55-62. PubMed ID: 6975467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin and breast cancer risk.
    Ingram DM; Nottage EM; Roberts AN
    Med J Aust; 1990 Oct; 153(8):469-73. PubMed ID: 2215338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total and lipid-bound serum sialic acid in benign and malignant breast disease.
    Romppanen J; Eskelinen M; Tikanoja S; Mononen I
    Anticancer Res; 1997; 17(2B):1249-53. PubMed ID: 9137482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of serum ferritin and lactate dehydrogenase in benign and malignant disease of breast.
    Kher A; Moghe G; Deshpande A
    Indian J Pathol Microbiol; 1997 Jul; 40(3):321-6. PubMed ID: 9354001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.